Young A Yoo1, Rajita Vatapalli1, Barbara Lysy1, Hanlin Mok1, Mohamed M Desouki2, Sarki A Abdulkadir1,3,4. 1. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL. 2. Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN. 3. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL. 4. The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
Abstract
BACKGROUND: Recurrence following androgen-deprivation therapy is associated with adverse clinical outcomes in prostate cancer, but the cellular origins and molecular mechanisms underlying this process are poorly defined. We previously identified a population of castration-resistant luminal progenitor cells expressing Bmi1 in the normal mouse prostate that can serve as a cancer cell-of-origin. Here, we investigate the potential of Bmi1-expressing tumor cells that survive castration to initiate recurrence in vivo. METHODS: We employed lineage retracing in Bmi1-CreER; R26R-confetti; Ptenf/f transgenic mice to mark and follow the fate of emerging recurrent tumor clones after castration. A tissue recombination strategy was used to rescue transgenic mouse prostates by regeneration as grafts in immunodeficient hosts. We also used a small molecule Bmi1 inhibitor, PTC-209, to directly test the role of Bmi1 in recurrence. RESULTS: Transgenic prostate tumors (n = 17) regressed upon castration but uniformly recurred within 3 months. Residual regressed tumor lesions exhibited a transient luminal-to-basal phenotypic switch and marked cellular heterogeneity. Additionally, in these lesions, a subpopulation of Bmi1-expressing castration-resistant tumor cells overexpressed the stem cell reprogramming factor Sox2 (mean [SD] = 41.1 [3.8]%, n = 10, P < .001). Bmi1+Sox2+ cells were quiescent (BrdU+Bmi1+Sox2+ at 3.4 [1.5]% vs BrdU+Bmi1+Sox2- at 18.8 [3.4]%, n = 10, P = .009), consistent with a cancer stem cell phenotype. By lineage retracing, we established that recurrence emerges from the Bmi1+ tumor cells in regressed tumors. Furthermore, treatment with the small molecule Bmi1 inhibitor PTC-209 reduced Bmi1+Sox2+ cells (6.1 [1.4]% PTC-209 vs 38.8 [2.3]% vehicle, n = 10, P < .001) and potently suppressed recurrence (retraced clone size = 2.6 [0.5] PTC-209 vs 15.7 [5.9] vehicle, n = 12, P = .04). CONCLUSIONS: These results illustrate the utility of lineage retracing to define the cellular origins of recurrent prostate cancer and identify Bmi1+Sox2+ cells as a source of recurrence that could be targeted therapeutically.
BACKGROUND: Recurrence following androgen-deprivation therapy is associated with adverse clinical outcomes in prostate cancer, but the cellular origins and molecular mechanisms underlying this process are poorly defined. We previously identified a population of castration-resistant luminal progenitor cells expressing Bmi1 in the normal mouse prostate that can serve as a cancer cell-of-origin. Here, we investigate the potential of Bmi1-expressing tumor cells that survive castration to initiate recurrence in vivo. METHODS: We employed lineage retracing in Bmi1-CreER; R26R-confetti; Ptenf/f transgenic mice to mark and follow the fate of emerging recurrent tumor clones after castration. A tissue recombination strategy was used to rescue transgenic mouse prostates by regeneration as grafts in immunodeficient hosts. We also used a small molecule Bmi1 inhibitor, PTC-209, to directly test the role of Bmi1 in recurrence. RESULTS:Transgenic prostate tumors (n = 17) regressed upon castration but uniformly recurred within 3 months. Residual regressed tumor lesions exhibited a transient luminal-to-basal phenotypic switch and marked cellular heterogeneity. Additionally, in these lesions, a subpopulation of Bmi1-expressing castration-resistant tumor cells overexpressed the stem cell reprogramming factor Sox2 (mean [SD] = 41.1 [3.8]%, n = 10, P < .001). Bmi1+Sox2+ cells were quiescent (BrdU+Bmi1+Sox2+ at 3.4 [1.5]% vs BrdU+Bmi1+Sox2- at 18.8 [3.4]%, n = 10, P = .009), consistent with a cancer stem cell phenotype. By lineage retracing, we established that recurrence emerges from the Bmi1+ tumor cells in regressed tumors. Furthermore, treatment with the small molecule Bmi1 inhibitor PTC-209 reduced Bmi1+Sox2+ cells (6.1 [1.4]% PTC-209 vs 38.8 [2.3]% vehicle, n = 10, P < .001) and potently suppressed recurrence (retraced clone size = 2.6 [0.5] PTC-209 vs 15.7 [5.9] vehicle, n = 12, P = .04). CONCLUSIONS: These results illustrate the utility of lineage retracing to define the cellular origins of recurrent prostate cancer and identify Bmi1+Sox2+ cells as a source of recurrence that could be targeted therapeutically.
Authors: Geert J L H van Leenders; Danny Dukers; Daphne Hessels; Susan W M van den Kieboom; Christina A Hulsbergen; J Alfred Witjes; Arie P Otte; Chris J Meijer; Frank M Raaphorst Journal: Eur Urol Date: 2006-11-17 Impact factor: 20.096
Authors: Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: M Schmitz; A Temme; V Senner; R Ebner; S Schwind; S Stevanovic; R Wehner; G Schackert; H K Schackert; M Fussel; M Bachmann; E P Rieber; B Weigle Journal: Br J Cancer Date: 2007-03-20 Impact factor: 7.640
Authors: R Vatapalli; V Sagar; Y Rodriguez; J C Zhao; K Unno; S Pamarthy; B Lysy; J Anker; H Han; Y A Yoo; M Truica; Z R Chalmers; F Giles; J Yu; D Chakravarti; B Carneiro; S A Abdulkadir Journal: Nat Commun Date: 2020-08-19 Impact factor: 14.919
Authors: Hisham F Bahmad; Mohammad Jalloul; Joseph Azar; Maya M Moubarak; Tamara Abdul Samad; Deborah Mukherji; Mohamed Al-Sayegh; Wassim Abou-Kheir Journal: Front Genet Date: 2021-03-26 Impact factor: 4.599
Authors: Larischa de Wet; Anthony Williams; Marc Gillard; Steven Kregel; Sophia Lamperis; Lisa C Gutgesell; Jordan E Vellky; Ryan Brown; Kelly Conger; Gladell P Paner; Heng Wang; Elizabeth A Platz; Angelo M De Marzo; Ping Mu; Jonathan L Coloff; Russell Z Szmulewitz; Donald J Vander Griend Journal: Oncogene Date: 2022-01-24 Impact factor: 8.756
Authors: Marc Carceles-Cordon; W Kevin Kelly; Leonard Gomella; Karen E Knudsen; Veronica Rodriguez-Bravo; Josep Domingo-Domenech Journal: Nat Rev Urol Date: 2020-03-16 Impact factor: 14.432